Manufacturers Life Insurance Company, The Eiger Bio Pharmaceuticals, Inc. Transaction History

Manufacturers Life Insurance Company, The

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Aug 11, 2023	SELL	$6.04 - $9.66 $4,445 - $7,109	-736 Reduced 4.14%	17,061 $128,000
Q3 2022 Nov 03, 2022	SELL	$6.04 - $9.66 $4,445 - $7,109	-736 Reduced 4.14%	17,061 $128,000
Q2 2022 Aug 11, 2023	BUY	$4.99 - $8.96 $18,772 - $33,707	3,762 Added 26.8%	17,797 $112,000
Q2 2022 Aug 15, 2022	BUY	$4.99 - $8.96 $18,772 - $33,707	3,762 Added 26.8%	17,797 $112,000
Q1 2022 Aug 11, 2023	BUY	$3.84 - $9.74 $53,894 - $136,700	14,035 New	14,035 $116,000
Q1 2022 May 20, 2022	BUY	$3.84 - $9.74 $9,488 - $24,067	2,471 Added 21.37%	14,035 $116,000
Q4 2021 Feb 16, 2022	BUY	$5.12 - $8.19 $59,207 - $94,709	11,564 New	11,564 $60,000
Q3 2021 Nov 12, 2021	SELL	$6.68 - $9.1 $146,305 - $199,308	-21,902 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$7.82 - $9.23 $19,870 - $23,453	2,541 Added 13.12%	21,902 $187,000
Q1 2021 May 03, 2021	SELL	$8.44 - $12.66 $6,954 - $10,431	-824 Reduced 4.08%	19,361 $171,000
Q4 2020 Feb 12, 2021	BUY	$7.98 - $12.29 $33,380 - $51,409	4,183 Added 26.14%	20,185 $248,000
Q3 2020 Nov 09, 2020	BUY	$7.96 - $12.42 $8,740 - $13,637	1,098 Added 7.37%	16,002 $130,000
Q2 2020 Aug 10, 2020	SELL	$5.4 - $13.37 $7,311 - $18,102	-1,354 Reduced 8.33%	14,904 $144,000
Q1 2020 May 15, 2020	BUY	$4.91 - $14.7 $6,137 - $18,375	1,250 Added 8.33%	16,258 $111,000
Q4 2019 Feb 14, 2020	SELL	$9.77 - $15.66 $11,294 - $18,102	-1,156 Reduced 7.15%	15,008 $224,000
Q3 2019 Nov 12, 2019	BUY	$9.59 - $12.0 $795 - $996	83 Added 0.52%	16,164 $170,000
Q2 2019 Aug 14, 2019	BUY	$9.54 - $14.96 $153,412 - $240,571	16,081 New	16,081 $170,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.